Glucagon Therapy for Muscle Glycogenosis
| Project/Area Number |
59870040
|
|---|
| Research Category |
Grant-in-Aid for Developmental Scientific Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
内分泌・代謝学
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
1984 – 1985
|
| Project Status |
Completed (Fiscal Year 1985)
|
| Budget Amount *help |
¥7,900,000 (Direct Cost: ¥7,900,000)
Fiscal Year 1985: ¥1,900,000 (Direct Cost: ¥1,900,000)
Fiscal Year 1984: ¥6,000,000 (Direct Cost: ¥6,000,000)
|
|---|
| Keywords | glycogenosis / phosphorylase / phosphofructokinase / glucagon / 骨格筋 |
|---|
| Research Abstract |
Glucagon injection was quite useful for alleviating muscular symptoms in the patients with type V glycogenosis we recently encountered. In this study, to develop a new practical treatment for muscle glycogenosis, we tried to elucidate the biochemical mechanism of glucagon benefit and to devise the therapeutical method of glucagon administration. The results were as follows:
1. We clearly demonstrated in bicycle ergometer exercise tests that glucagon injection enhanced exercise performance of patients with type V glycogenosis, while it produced no improvement in patients with type VII glycogenosis.
2. Lactate was produced and released from exercising muscles after glucagon injection in type V glycogenosis but not in type VII glycogenosis.
3. In type V glycogenosis, exercised-induced lactate production was also observed after administration of glucose or glucose plus insulin. Thus we concluded the benefical effect of glucagon in type V glycogenosis is due to the enhanced utilization of circulating glucose through the muscular glycolytic pathway realized in the coexistence of hyperglycemia and hyperinsulinemia.
4. Plasma glucose and insulin levels rose more greatly and the high levels persisted for longer periods after glucagon injection subcutaneously than intravenously. The maximal effects of glucagon were observed after 30 min of subcutaneous injection. Subcutaneous pulsatile (every 30 min) glucagon infusion was carried out with a portable pump developed in this study in healthy volunteers, and prolonged hyperglycemia and hyperinsulinemia were achieved with no apparent adverse effects. Glucagon therapy is now applicable to clinical practice for at least some types of muscle glycogenosis.
|
Report
(1 results)
Research Products
(6 results)
